Matches in Wikidata for { <http://www.wikidata.org/entity/Q44253511> ?p ?o ?g. }
- Q44253511 description "2002 nî lūn-bûn" @default.
- Q44253511 description "2002年の論文" @default.
- Q44253511 description "2002年学术文章" @default.
- Q44253511 description "2002年学术文章" @default.
- Q44253511 description "2002年学术文章" @default.
- Q44253511 description "2002年学术文章" @default.
- Q44253511 description "2002年学术文章" @default.
- Q44253511 description "2002年學術文章" @default.
- Q44253511 description "2002年學術文章" @default.
- Q44253511 description "2002年學術文章" @default.
- Q44253511 description "2002年學術文章" @default.
- Q44253511 description "2002年學術文章" @default.
- Q44253511 description "2002年學術文章" @default.
- Q44253511 description "2002년 논문" @default.
- Q44253511 description "article científic" @default.
- Q44253511 description "article scientific" @default.
- Q44253511 description "article scientifique (publié 2002)" @default.
- Q44253511 description "articol științific" @default.
- Q44253511 description "articolo scientifico" @default.
- Q44253511 description "artigo científico (publicado na 2002)" @default.
- Q44253511 description "artigo científico (publicado na 2002)" @default.
- Q44253511 description "artigo científico" @default.
- Q44253511 description "artikull shkencor" @default.
- Q44253511 description "artikulong pang-agham" @default.
- Q44253511 description "artykuł naukowy" @default.
- Q44253511 description "artículo científico publicado en 2002" @default.
- Q44253511 description "artículu científicu espublizáu en 2002" @default.
- Q44253511 description "bilimsel makale" @default.
- Q44253511 description "bài báo khoa học" @default.
- Q44253511 description "mokslinis straipsnis" @default.
- Q44253511 description "naučni članak" @default.
- Q44253511 description "scienca artikolo" @default.
- Q44253511 description "scientific article" @default.
- Q44253511 description "teaduslik artikkel" @default.
- Q44253511 description "tieteellinen artikkeli" @default.
- Q44253511 description "tudományos cikk" @default.
- Q44253511 description "vedecký článok" @default.
- Q44253511 description "vetenskaplig artikel" @default.
- Q44253511 description "videnskabelig artikel (udgivet 2002)" @default.
- Q44253511 description "vitenskapelig artikkel" @default.
- Q44253511 description "vitskapeleg artikkel" @default.
- Q44253511 description "vědecký článek" @default.
- Q44253511 description "wetenschappelijk artikel" @default.
- Q44253511 description "wissenschaftlicher Artikel" @default.
- Q44253511 description "επιστημονικό άρθρο" @default.
- Q44253511 description "мақолаи илмӣ" @default.
- Q44253511 description "мақолаи илмӣ" @default.
- Q44253511 description "наукова стаття, опублікована в грудні 2002" @default.
- Q44253511 description "научна статия" @default.
- Q44253511 description "научная статья" @default.
- Q44253511 description "научни чланак" @default.
- Q44253511 description "научни чланак" @default.
- Q44253511 description "գիտական հոդված" @default.
- Q44253511 description "מאמר מדעי" @default.
- Q44253511 description "سائنسی مضمون" @default.
- Q44253511 description "مقالة علمية تنشرت ف 1 دجنبر 2002" @default.
- Q44253511 description "مقالة علمية" @default.
- Q44253511 description "مقالهٔ علمی" @default.
- Q44253511 description "২০০২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q44253511 description "บทความทางวิทยาศาสตร์" @default.
- Q44253511 description "სამეცნიერო სტატია" @default.
- Q44253511 name "Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up" @default.
- Q44253511 name "Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up" @default.
- Q44253511 type Item @default.
- Q44253511 label "Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up" @default.
- Q44253511 label "Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up" @default.
- Q44253511 prefLabel "Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up" @default.
- Q44253511 prefLabel "Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up" @default.
- Q44253511 P1433 Q44253511-FD578CF1-FAA7-41E2-BE12-9FEB92F9B115 @default.
- Q44253511 P1476 Q44253511-7CB2B9C2-F5B7-477B-8E23-875B844749CE @default.
- Q44253511 P2093 Q44253511-133C74C0-E28E-4580-AE3C-14167F596BB8 @default.
- Q44253511 P2093 Q44253511-200143D3-6A7E-4F92-9438-372CD124CFB6 @default.
- Q44253511 P2093 Q44253511-218C3B87-7CD4-4F8B-9D1F-7D2BE38B82EC @default.
- Q44253511 P2093 Q44253511-2722A42A-BF87-4EBA-B34A-F0AB61EC1699 @default.
- Q44253511 P2093 Q44253511-37F3EC9B-3762-4854-ACF0-005854C83135 @default.
- Q44253511 P2093 Q44253511-6E571265-8F5B-4399-BF6D-0B44E317329E @default.
- Q44253511 P2093 Q44253511-A866C613-4B5F-44DD-84F6-57BDF7326F08 @default.
- Q44253511 P2093 Q44253511-AA31FD8A-DBB7-4726-A102-C7819EAC1587 @default.
- Q44253511 P2093 Q44253511-B1B8C910-4D49-4460-9131-37D5D9BCF413 @default.
- Q44253511 P2093 Q44253511-C0768415-B713-4B1A-AB3F-9D85306EA588 @default.
- Q44253511 P2093 Q44253511-CD690DB4-8B4C-42D6-9CE6-3DA2C362432B @default.
- Q44253511 P2093 Q44253511-DC136468-E246-4844-BB77-76703ACE3764 @default.
- Q44253511 P2093 Q44253511-EAB225A9-FB3C-4F2F-A937-0BD02CF2001B @default.
- Q44253511 P304 Q44253511-303DE6BA-446C-4607-A9FC-11A746553300 @default.
- Q44253511 P31 Q44253511-D5756D29-F1DE-44A0-B806-F2846C87DB80 @default.
- Q44253511 P356 Q44253511-E804DCF6-E1C7-4119-A981-FF57E8F18157 @default.
- Q44253511 P407 Q44253511-14ABB18B-39E3-49A7-80F5-0B6B1F2AFC71 @default.
- Q44253511 P433 Q44253511-72F1DA38-3DCC-4E5B-8B2B-0E23F9EA4EED @default.
- Q44253511 P478 Q44253511-9E98CDEF-B837-4874-8A2D-B2404A9D7B40 @default.
- Q44253511 P50 Q44253511-80CA61EC-7A0E-4715-AD4F-6C83FF9E70A6 @default.
- Q44253511 P577 Q44253511-B7849789-8F1B-4EA4-A013-344D9A4C4C2E @default.
- Q44253511 P698 Q44253511-FE4F0EEB-C4E6-45D9-937E-FB0CCEF04A3C @default.
- Q44253511 P921 Q44253511-1E1C97DF-1106-40CE-A3D6-E128A347BC77 @default.
- Q44253511 P921 Q44253511-53AB9247-321A-4159-A729-BDA65F662A31 @default.
- Q44253511 P921 Q44253511-71278145-5848-475B-AF8D-F3F4117FD3D6 @default.
- Q44253511 P921 Q44253511-BA3FAF0D-F8ED-4394-9E72-7A1778D2170E @default.
- Q44253511 P356 JCO.2002.12.111 @default.
- Q44253511 P698 12488411 @default.
- Q44253511 P1433 Q400292 @default.
- Q44253511 P1476 "Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up" @default.